Literature DB >> 11220626

The first constant-domain (CH1) exon of human IGHG2 is polymorphic and in strong linkage disequilibrium with the CH2 exon polymorphism encoding the G2m(n+) allotype in Caucasians.

L Hougs1, A Svejgaard, T Barington.   

Abstract

Here we describe a hitherto unknown proline/threonine polymorphism at residue 72 of the human IgG2 CH1 domain (EU numbering 189) and show that it is linked to the known valine/methionine polymorphism at residue 52 of CH2 (EU numbering 282) defining the G2m(n+)/G2m(n-) allotypes. We sequenced the entire constant region of the heavy-chain gene for secreted IgG2 in five IGHG2*02 homozygous individuals covering CH1, hinge, CH2, and CH3 regions (approximately 2 kb). Proline 72 in CH1 of G2m(n-) is changed to threonine in the G2m(n+) [G2m(23)] allotype. Based on the crystal structure of human IgG1, this amino acid position is expected to be surface exposed in IgG2. Besides this structural difference, we identified two silent nucleotide polymorphisms in the CH1 region and seven in the introns. Finally, we developed a sequence-specific PCR typing system detecting the polymorphisms in the CH1 and CH2 regions. We typed 64 Danish Caucasians and found that the CH1 and CH2 region polymorphisms are in complete linkage disequilibrium in this population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11220626     DOI: 10.1007/s002510000278

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  2 in total

1.  IgG2m4, an engineered antibody isotype with reduced Fc function.

Authors:  Zhiqiang An; Gail Forrest; Renee Moore; Michael Cukan; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jing Zhang Zhao; Ping Lu; Jin Hua; Christopher R Gibson; Barrett R Harvey; Donna Montgomery; Dennis Zaller; Fubao Wang; William Strohl
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 2.  Human immunoglobulin allotypes: possible implications for immunogenicity.

Authors:  Roy Jefferis; Marie-Paule Lefranc
Journal:  MAbs       Date:  2009 Jul-Aug       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.